Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2024-04-29 Board/Management Inform…
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 29, 2024, reporting the appointment of a new Chief Financial Officer and the resignation of the previous CFO. It details the employment agreement terms, severance, and transition arrangements. There are no financial statements or financial performance data included. The content focuses on management changes, specifically at the executive level. According to the filing definitions, announcements of changes in senior management fall under Board/Management Information (MANG). The document length is sufficient and contains detailed information about the management change, not just a brief announcement or a report publication notice. Therefore, the appropriate classification is MANG with high confidence.
2024-04-29 English
ARS
Annual Report
2024-04-23 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or additional materials related to a shareholder meeting. It includes information about voting items such as election of directors and ratification of auditors, which are typical contents of proxy solicitation materials. The text explicitly mentions 'Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934' and 'Definitive Additional Materials.' It also provides instructions for voting and details about the annual meeting. The document length is under 5,000 characters and primarily serves to inform shareholders about voting matters rather than presenting financial data or detailed reports. Therefore, this document fits the category of Proxy Solicitation & Information Statement (PSI).
2024-04-23 English
DEF 14A
Proxy Solicitation & Information Statement
2024-04-23 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-18 English
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
Director's Dealing
2024-04-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.